Protocol Ledger

NCT05112601 · Phase II · RECRUITING

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Interventional Phase II clinical trial protocol NCT05112601 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-02 Enrollment: 81 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05112601
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)81 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05112601
Protocol FieldVerified Registry Value
NCT IdentifierNCT05112601
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment81 participants (ESTIMATED)
Registered Start Date2022-06-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI